Pictet Asset Management Holding SA Has $11.42 Million Stock Holdings in Guardant Health, Inc. $GH

Pictet Asset Management Holding SA decreased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 21.2% during the 1st quarter, Holdings Channel reports. The fund owned 131,141 shares of the company’s stock after selling 35,243 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Guardant Health were worth $11,418,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of GH. World Investment Advisors acquired a new position in shares of Guardant Health in the 4th quarter valued at $1,664,000. Algert Global LLC raised its stake in Guardant Health by 169.1% during the 3rd quarter. Algert Global LLC now owns 120,114 shares of the company’s stock worth $7,505,000 after buying an additional 75,474 shares during the period. Iron Triangle Partners LP raised its stake in Guardant Health by 33.3% during the 3rd quarter. Iron Triangle Partners LP now owns 400,000 shares of the company’s stock worth $24,992,000 after buying an additional 100,000 shares during the period. Capricorn Fund Managers Ltd lifted its holdings in Guardant Health by 197.8% during the fourth quarter. Capricorn Fund Managers Ltd now owns 107,787 shares of the company’s stock worth $11,009,000 after acquiring an additional 71,587 shares in the last quarter. Finally, Atika Capital Management LLC lifted its holdings in Guardant Health by 49.1% during the third quarter. Atika Capital Management LLC now owns 133,000 shares of the company’s stock worth $8,310,000 after acquiring an additional 43,800 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Down 1.6%

Shares of GH opened at $167.98 on Friday. Guardant Health, Inc. has a twelve month low of $40.35 and a twelve month high of $172.60. The stock has a market capitalization of $22.27 billion, a P/E ratio of -49.55 and a beta of 1.59. The company has a 50 day moving average of $118.33 and a 200-day moving average of $105.66.

Insider Buying and Selling

In other news, CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the sale, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Chris Freeman sold 24,406 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the completion of the transaction, the insider directly owned 60,034 shares of the company’s stock, valued at $7,124,234.78. This represents a 28.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 712,513 shares of company stock worth $90,921,587 over the last three months. Company insiders own 5.60% of the company’s stock.

Analyst Ratings Changes

GH has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Sanford C. Bernstein boosted their price objective on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday. UBS Group set a $150.00 target price on Guardant Health in a research note on Wednesday, June 24th. The Goldman Sachs Group assumed coverage on shares of Guardant Health in a report on Friday, June 5th. They set a “buy” rating and a $165.00 target price on the stock. Finally, TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Guardant Health has an average rating of “Moderate Buy” and an average price target of $147.32.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.